Skip to Content

WPI 900 (Glipizide Extended Release 2.5 mg)

Pill with imprint WPI 900 is Yellow, Round and has been identified as Glipizide Extended Release 2.5 mg. It is supplied by Watson Pharmaceuticals.

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 2.5 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 900

Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900 Front
Glipizide extended release 2.5 mg WPI 900 Back
Glipizide extended release 2.5 mg WPI 900
Glipizide extended release 2.5 mg WPI 900

Glipizide Extended Release

Imprint
WPI 900
Strength
2.5 mg
Color
Yellow
Size
6.00 mm
Shape
Round
Availability
Prescription only
Drug Class
Sulfonylureas
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Watson Pharmaceuticals
Inactive Ingredients
acetyltributyl citrate, ammonia, butyl alcohol, ferrosoferric oxide, hydroxyethyl cellulose (2000 cps at 1%), isopropyl alcohol, lactose monohydrate, magnesium stearate, methacrylic acid - methyl methacrylate copolymer (1:1), polyethylene glycol 400, propylene glycol, shellac, FD&C Yellow No. 6

Note: Inactive ingredients may vary.

Labelers / Repackagers

NDC Code Labeler / Repackager
00591-0900 Watson Pharmaceuticals, Inc.
68084-0295 Amerisource Health Services

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.